<DOC>
	<DOCNO>NCT00465842</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) fifth common cancer world poor prognosis , annual mortality almost equivalent incidence . This mainly due late diagnosis co-morbid liver dysfunction . HCC prevalent region West due prevalent Hepatitis B infection carrier . At time diagnosis , 10 - 20 % HCC patient candidate liver resection transplantation . Almost 40-50 % patient poor liver function co-morbid condition supportive care offer . Thus median survival time 18-24 month resectable disease , 6 month unresectabe disease 3 month metastatic disease . Current screen method HCC high risk patient depend alpha-fetoprotein ( AFP ) ultrasound liver . Neither test sensitive specific enough early detection . Therefore , early diagnosis novel protein biomarkers need urgently may provide hope improve treatment outcome . Our preliminary study 49 HCC patient identify several protein truncate complement C3a , albumin , B2 microglobulin , may potentially helpful early diagnosis . We start large prospective longitudinal study July 2006 , nearly 100 patient accrue . This application extend expand current study . We aim ( ) identify validate novel protein biomarkers early diagnosis HCC ( ii ) conduct longitudinal proteomics up-to-date method discover new biomarker early detection prognostication HCC ( iii ) set gene plasma depository clinical database HCC collaboration Singapore Tissue Network .</brief_summary>
	<brief_title>Protein Biomarker Hepatocellular Carcinoma</brief_title>
	<detailed_description>Up 40 % HCC patient normal AFP . Moreover , AFP also elevate patient cirrhosis exacerbation chronic hepatitis . Prospective study evaluate value AFP HCC surveillance report sensitivity 39-64 % , specificity 76-91 % positive predictive value 9 -32 % 9-11 . Recently , small handful biomarkers identify blood 49 HCC patient SELDI / MS proteomic analysis blood specificity sensitivity 90 % 12 , 13 . These truncated complement C3a , albumin , B2 microglobulin , histidine-rich glycoprotein . In addition , insulin growth factor ( IGF ) bind protein show novel biomarkers HCC 14-17 . A large prospective study necessary validate finding . Other investigator also use Surface-enhanced laser desorption / ionization time-of-flight mass spectrometry ( SELDI ) study proteomics HCC . Most study include small number patient include independent test set report reproducibility time . Thus , controversy continue technology SELDI validation finding . Nevertheless , Ward et al report Kappa Lumda immunoglobulin light chain elevated average pf 50 % serum HCC patient ( p &lt; 0.001 , sensitivity 94 % , specificity 86 % ) Hepatitis C relate cirrhosis 18 . Schwegler et al report SELDI-TOF MS profile serum distinguish chronic Hepatitis C HCV- related HCC sensitivity 61 % specificity 76 % . Sensitivity specificity improve addition AFP , des-gamma carboxyprothrombin , GP73 19 . Other report also indicate potential marker heat-shock protein 27 20 complement C3a 21 . However , study lack prospective longitudinal follow-up multiple serum sample patient . Our trial design test change proteomic overtime identify early possible biomarkers HCC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Group A : Normal volunteer without history liver disease normal liver function test ( LFT ) , include total protein/Albumin , LDH , ALT , AST , GGT , total bilirubin , direct indirect bilirubin belong group B . Volunteers screen use questionnaire . Those deem suitable ask blood test do . All blood test do free charge subject . Group B : Hepatitis B C carrier normal liver function . Group C : Hepatitis B C carrier abnormal liver function . Group D : Liver cirrhosis , proven liver biopsy clinical evidence , varix CT scan indicative portal hypertension . Group E : HCC patient resection . Group F : Unresectable HCC patient treatment . Group G : HCC patient active malignant disease palliative care offer . Signed Informed Consent â‰¥ 18 year age In trial , diagnosis HCC establish either ( ) know hepatitis B C carrier , space occupy lesion ( ) liver AFP &gt; 400ng/ml ( b ) cytological histological confirmation biopsy There exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>Liver Cirrhosis</keyword>
	<keyword>HCC</keyword>
</DOC>